Biomarkers are important in MS, as they can potentially help with diagnosing patients, inform about disease prognosis, and help monitor disease activity and progression. Neurofilament light chain (NfL) is one of the most promising biomarkers in MS, but is it ready for clinical practice? In this episode, Professor of Neurology Finn Sellebjerg will tell us about the potential and limitations of this exciting biomarker.
Podden och tillhörande omslagsbild på den här sidan tillhör
Sanofi. Innehållet i podden är skapat av Sanofi och inte av,
eller tillsammans med, Poddtoppen.
